Healthcare Industry News: osteoporosis
News Release - September 23, 2008
Halozyme Therapeutics Appoints Head of Endocrinology Clinical DevelopmentSAN DIEGO, Sept. 23 (HSMN NewsFeed) -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that Douglas B. Muchmore, MD, has joined the company as Vice President, Endocrinology Clinical Development.
"I am thrilled to welcome an individual of Dr. Muchmore's high caliber and achievement to the Halozyme leadership team. He is a widely respected endocrinologist for his talent and experience in drug development, clinical medicine, and regulatory interaction in academic, research, and corporate settings. Doug's addition to Halozyme will immediately add value to the advancement of our insulin and bisphosphonate programs," said Jonathan Lim, MD, President and CEO of Halozyme Therapeutics. "His decision to join Halozyme further validates the quality of our research programs, the promise of our technology, and the exciting potential of our ongoing product development efforts. Doug Muchmore exemplifies Halozyme's steadfast commitment to attract, develop, and retain top talent with extensive experience in each of our therapeutic disciplines and in all functional areas of the company."
Dr. Muchmore has more than 30 years of professional experience in clinical drug development, clinical research trial design and implementation, and the practice of endocrinology. His experience spans all stages of clinical development in the field of endocrinology, where he has direct experience with diabetes and osteoporosis indications. Prior to joining Halozyme, Dr. Muchmore served as Medical Fellow II on the Insulins and Devices Team and a member of the Diabetes Platform Team at Eli Lilly and Co. He acted as the key scientific developer and lead medical negotiator for FDA interactions for AIR® Insulin, Lilly's inhaled insulin program.
During its first five years of development, Dr. Muchmore was the sole physician on the Lilly inhaled insulin development effort and the AIR® Insulin team. He was responsible for designing and executing all of the early phase studies and he successfully advanced the program to Phase III. Dr. Muchmore's responsibilities at Lilly also included the evaluation of promising new technologies, which is how he became aware of Halozyme's proprietary insulin program and its recombinant human hyaluronidase enzyme technology. Prior to leading Lilly's inhaled insulin program, Dr. Muchmore served on the Evista Product Team for osteoporosis and breast cancer indications from 1995 to 1999 and as its Physician Group Leader from 1997 to 1999. He is the recipient of numerous awards for professional achievement, including the Eli Lilly Global Brand Development Team Leadership Award in 2007.
From 1982 to 1995, Dr. Muchmore was staff endocrinologist at the Scripps Clinic and Research Foundation, holding additional appointments as Clinical Assistant Professor of Medicine, UCSD, and Senior Physician, The Whittier Institute for Diabetes and Endocrinology. Dr. Muchmore also served as visiting endocrinologist at the Logan Heights Community Clinic in San Diego. He received his AB degree in Biological Sciences from Stanford University, his MD from UCSD, and initiated his internship and residency training in internal medicine at the University of Washington Affiliated Hospitals in Seattle, Washington. He finished his residency training in 1978 at the Martinez Veterans Hospital, affiliated with the University of California, Davis. Dr. Muchmore completed a Fellowship in Endocrinology and Metabolism, followed by Instructorship in Medicine, at University Hospital, Seattle in 1982.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, metabolism, oncology, and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase®, for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. Halozyme also has a number of different enzymes in its portfolio that target significant areas of unmet medical need. For more information visit http://www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the expected roles and responsibilities of management) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.
Source: Halozyme Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.